NCT05908448 - The True Vie I3 Continuous Glucose Monitoring System in Pediatric Patients With Type 1 Diabetes Mellitus | Biotech Hunter

Enrollment

134

Participants

Timeline

Start Date

February 7, 2024

Primary Completion Date

October 18, 2024

Study Completion Date

November 13, 2024

Conditions

T1DM - Type 1 Diabetes Mellitus

Interventions

DEVICE

13 CGM (continuous glucose monitor)

The I3 CGM consists of three main components: a Sensor Pack (Applicator-Sensor assembly), a Transmitter Pack (with Bluetooth Low Energy (BLE)) and a mobile application (I3 CGM App). The user can view their glucose data on the I3 CGM App running on a compatible mobile device.

Trial Locations (1)

30318

Atlanta Diabetes Associates, Atlanta

All Listed Sponsors

collaborator

Atlanta Diabetes Associates

OTHER

lead

Sinocare

INDUSTRY